With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.
300 mg (1.4 mmol) of 4-methyl-4′-carboxy-2,2′-bipyridine was weighed out296 mg (1.64 mmol) of 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDC ¡¤ HCl) and 161 mg (1.4 mmol) of N-hydroxysuccinimide (NHS) , Evacuated and protected by nitrogen. Then, 6 mL of dry DMF and 0.4 mL of dry triethylamine were added to react for 12 h at 25 C., 1.5 mL of ethylamine and 0.6 mL of triethylamine were added, and the reaction was continued at 25 C. for 24 h. The reaction was completed and the residue was evaporated under reduced pressure. The residue was taken up in dichloromethane (3 ¡Á 100 mL) and the organic phase was spin-dried and packed in silica gel. The product was isolated and purified in 30% yield
103946-54-9, As the paragraph descriping shows that 103946-54-9 is playing an increasingly important role.
Reference£º
Patent; Nanjing University of Posts and Telecommunications; Zhang Yin; Zhang Taiwei; Sun Guanglan; Gao Pengli; Chen Xiaojiao; Zhao Qiang; Liu Shujuan; Huang Wei; (16 pag.)CN107417737; (2017); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI